Side-by-side · Research reference
IGF-DESvsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED8/60 cited
BAnimal-StrongAUTO-DRAFTED13/39 cited
IGF-DES
IGF-1 Analogue · Truncated N-Terminal
~10×Potency vs IGF-1
ReducedIGFBP binding
ResearchStatus
Injection (local or systemic) · Research protocols onlyBredehöft 2008
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
IGF-DES
KPV
Primary target
IGF-1 receptor (IGF1R)Shields 2007
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
Unknown — no human endocrine feedback data
No melanocortin receptor binding
Origin
Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
—
—
02Dosage Protocols
Parameter
IGF-DES
KPV
Research dose range
10–100 ng/mL (in vitro); μg doses (animal models)
Highly context-dependent; no standardized human protocol.
—
Route
Subcutaneous or intramuscular (local injection favored)
Local delivery maximizes tissue-specific uptake.
—
Frequency
Variable — daily to multiple times daily in research
Daily or 2–3× per week
Evidence basis
Animal models + in vitro only
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Human data
None — no clinical trials
—
Half-life
Shorter than IGF-1 due to reduced IGFBP binding
Rapid tissue uptake, limited systemic circulation.
Hours (estimated; rapid tissue uptake)
Lower / starter dose
—
100 mcg / day
Duration
—
4–8 weeks per cycle
Reconstitution
—
Bacteriostatic water (SQ form)
Timing
—
No specific time; often taken with / before meals (oral)
03Metabolic / Fat Loss Evidence
Parameter
IGF-DES
KPV
Primary mechanism
Indirect via muscle hypertrophy → metabolic rate elevation
—
Direct lipolysis
Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic
—
Prostate model
Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002
Context-specific anti-proliferative effect, not fat loss.
—
04Side Effects & Safety
Parameter
IGF-DES
KPV
Hypoglycemia risk
Theoretical — IGF-1 axis enhances glucose uptake
—
Mitogenic risk
Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002
—
Injection site reaction
Expected — erythema, irritation, local swelling
Mild irritation
Edema / Fluid retention
Possible via sodium retention (IGF-1 axis effect)
—
Human safety data
Absent — no human trials, all effects theoretical or extrapolated
—
Unknown long-term effects
No chronic dosing studies in humans; endocrine, metabolic consequences unknown
—
GI symptoms
—
Rare nausea (oral form)
Long-term safety
—
Limited human data
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
IGF-DES
- ·Active malignancy or history of cancer (mitogenic risk)
- ·Pregnancy / lactation (no safety data)
- ·Hypoglycemia disorders
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
IGF-DES
- ·Diabetes mellitus (unpredictable glucose effects)
- ·Renal or hepatic impairment (clearance unknown)
- ·Edema-prone conditions (heart failure, nephrotic syndrome)
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
IGF-DES
KPV
1. Research context only
Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.
Add 1 mL bacteriostatic water to vial per labelling.
2. Reconstitution (if lyophilized)
Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Injection site
Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.
Morning preferred; oral form taken with / before meals.
4. Timing
Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle gauge
27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.
29–31G insulin syringe (SQ form).
6. Monitoring
Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.
—
06Stack Synergy
IGF-DES
+ BPC-157
ModerateDes(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- BPC-157
- 250–500 mcg SQ, daily or twice daily
- Frequency
- Daily or per research protocol
- Primary benefit
- Accelerated muscle repair, enhanced hypertrophy, connective tissue support
+ TB-500
ModerateTB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- TB-500
- 2–5 mg SQ, 2× weekly
- Frequency
- Per research cycle
- Primary benefit
- Muscle hypertrophy, injury recovery, vascular support
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions